GLP-1 receptor drugs linking metabolism and gut inflammation in type 2 diabetes and inflammatory bowel disease

GLP-1 receptor agonists may reduce major adverse cardiovascular events (MACE) while lowering systemic inflammatory biomarkers.

• Obesity and type 2 diabetes are prevalent among individuals with inflammatory bowel disease (IBD).
• GLP-1 receptor agonists are associated with a reduction in MACE.
• These medications could also lower systemic inflammatory biomarkers.
• Observational data indicate that GLP-1 receptor agonists may be safe for IBD patients, with fewer hospitalizations and surgeries.
• Carefully designed prospective trials are warranted to further investigate these findings.

Simplified